These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 34013836)

  • 1. Central Precocious Puberty in an Infant with Sotos Syndrome and Response to Treatment.
    Kontbay T; Şıklar Z; Ceylaner S; Berberoğlu M
    J Clin Res Pediatr Endocrinol; 2022 Aug; 14(3):356-360. PubMed ID: 34013836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effectiveness of depot gonadotropin-releasing hormone analogue in the treatment of children with central precocious puberty.
    Clemons RD; Kappy MS; Stuart TE; Perelman AH; Hoekstra FT
    Am J Dis Child; 1993 Jun; 147(6):653-7. PubMed ID: 8506834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Central precocious puberty in a girl with Williams syndrome: the result of treatment with GnRH analogue.
    Utine GE; Alikasifoglu A; Alikasifoglu M; Tuncbilek E
    Eur J Med Genet; 2006; 49(1):79-82. PubMed ID: 16473313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accelerated versus slowly progressive forms of puberty in girls with precocious and early puberty. Gonadotropin suppressive effect and final height obtained with two different analogs.
    Lanes R; Soros A; Jakubowicz S
    J Pediatr Endocrinol Metab; 2004 May; 17(5):759-66. PubMed ID: 15237711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 3 Trial of a Small-volume Subcutaneous 6-Month Duration Leuprolide Acetate Treatment for Central Precocious Puberty.
    Klein KO; Freire A; Gryngarten MG; Kletter GB; Benson M; Miller BS; Dajani TS; Eugster EA; Mauras N
    J Clin Endocrinol Metab; 2020 Oct; 105(10):e3660-71. PubMed ID: 32738042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty.
    Lee PA; Klein K; Mauras N; Neely EK; Bloch CA; Larsen L; Mattia-Goldberg C; Chwalisz K
    J Clin Endocrinol Metab; 2012 May; 97(5):1572-80. PubMed ID: 22344198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of gonadotropin secretion by a long-acting gonadotropin-releasing hormone analog (leuprolide acetate, Lupron Depot) in children with precocious puberty.
    Kappy M; Stuart T; Perelman A; Clemons R
    J Clin Endocrinol Metab; 1989 Nov; 69(5):1087-9. PubMed ID: 2507570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A CASE OF SOTOS SYNDROME CAUSED BY A NOVEL VARIANT IN THE NSD1 GENE: A PROPOSED RATIONALE TO TREAT ACCOMPANYING PRECOCIOUS PUBERTY.
    Özcabi B; Akay G; Yesil G; Uyur Yalcin E; Kirmizibekmez H
    Acta Endocrinol (Buchar); 2020; 16(2):245-249. PubMed ID: 33029244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in body mass index during gonadotropin-releasing hormone agonist treatment for central precocious puberty and early puberty.
    Lee HS; Yoon JS; Roh JK; Hwang JS
    Endocrine; 2016 Nov; 54(2):497-503. PubMed ID: 27444748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single luteinizing hormone determination 2 hours after depot leuprolide is useful for therapy monitoring of gonadotropin-dependent precocious puberty in girls.
    Brito VN; Latronico AC; Arnhold IJ; Mendonca BB
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4338-42. PubMed ID: 15356030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of leuprolide in the treatment of central precocious puberty.
    Lee PA; Page JG
    J Pediatr; 1989 Feb; 114(2):321-4. PubMed ID: 2492599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sotos syndrome, infantile hypercalcemia, and nephrocalcinosis: a contiguous gene syndrome.
    Kenny J; Lees MM; Drury S; Barnicoat A; Van't Hoff W; Palmer R; Morrogh D; Waters JJ; Lench NJ; Bockenhauer D
    Pediatr Nephrol; 2011 Aug; 26(8):1331-4. PubMed ID: 21597970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 36-month treatment experience of two doses of leuprolide acetate 3-month depot for children with central precocious puberty.
    Lee PA; Klein K; Mauras N; Lev-Vaisler T; Bacher P
    J Clin Endocrinol Metab; 2014 Sep; 99(9):3153-9. PubMed ID: 24926950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Depot leuprolide acetate for treatment of precocious puberty.
    Parker KL; Lee PA
    J Clin Endocrinol Metab; 1989 Sep; 69(3):689-91. PubMed ID: 2503536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Congenital adrenal hyperplasia complicated by central precocious puberty: linear growth during infancy and treatment with gonadotropin-releasing hormone analog.
    Soliman AT; AlLamki M; AlSalmi I; Asfour M
    Metabolism; 1997 May; 46(5):513-7. PubMed ID: 9160816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment with gonadotropin-releasing hormone analogs (GnRHa) in childhood and adolescence].
    Comité Nacional de Endocrinología
    Arch Argent Pediatr; 2022 Feb; 120(1):S1-S8. PubMed ID: 35068132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Height prognosis of children with true precocious puberty and growth hormone deficiency: effect of combination therapy with gonadotropin releasing hormone agonist and growth hormone.
    Cara JF; Kreiter ML; Rosenfield RL
    J Pediatr; 1992 May; 120(5):709-15. PubMed ID: 1533661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gonadotropin-dependent precocious puberty in a patient with X-linked adrenal hypoplasia congenita caused by a novel DAX-1 mutation.
    Darcan S; Goksen D; Ozen S; Ozkinay F; Durmaz B; Lalli E
    Horm Res Paediatr; 2011 Feb; 75(2):153-6. PubMed ID: 20975255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anthropometric, metabolic, and reproductive outcomes of patients with central precocious puberty treated with leuprorelin acetate 3-month depot (11.25 mg).
    Ramos CO; Canton APM; Seraphim CE; Faria AG; Tinano FR; Mendonca BB; Latronico AC; Brito VN
    J Pediatr Endocrinol Metab; 2021 Nov; 34(11):1371-1377. PubMed ID: 34298591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoparathyroidism in a 3-year-old Korean boy with Sotos syndrome and a novel mutation in NSD1.
    Wejaphikul K; Cho SY; Huh R; Kwun Y; Lee J; Ki CS; Jin DK
    Ann Clin Lab Sci; 2015; 45(2):215-8. PubMed ID: 25887879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.